In a murine model of asthma, treatment with an analog of lipoxin A4 (LXA4) has a beneficial effect on both airway hyper-responsiveness and pulmonary inflammation, according to a recent report. The therapeutic effect of such agents appears to involve multiple mechanisms.
Previous reports indicate that lipoxins, a class of eicosanoids, can inhibit vascular responses and promote resolution of inflammation. However, these agents have not been tested in a well-qualified animal model of asthma.
The effects of a stable analogue of LXA4 on a murine model of asthma are described by Dr. Charles N. Serhan, from Brigham and Women’s Hospital in Boston, and colleagues in the August 12th online issue of Nature Medicine.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!